Thomas Gad compensation by year
Y-mAbs Therapeutics Summary Compensation Table · all 2 fiscal years held| Component | FY2023 | FY2024 |
|---|---|---|
| Salary | $664,899 | $579,752 |
| Bonus | $0 | $0 |
| Stock awards | $190,350 | $213,928 |
| Option awards | $1,152,506 | $949,349 |
| Non-equity incentive | $362,370 | $248,134 |
| Pension and deferred compensation | $0 | $0 |
| All other | $84,358 | $84,000 |
| Total | $2,454,483 | $2,075,163 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Y-mAbs Therapeutics, Inc. DEF 14A filed May 30, 2025, accession 0001558370-25-008299, and prior-year filings.
How this page was built: the Y-mAbs Therapeutics, Inc. filed document, accession 0001558370-25-008299. Every figure is read from that document and cited to the page and table it appears in. Filed May 30, 2025.
Equity holdings
unvested awards at FY2024 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 27,001 | $211,418 | — |
| RSU | 22,100 | $173,043 | — |
| Option | 27,588 | — | $15.73 |
| Option | 21,288 | — | $9.52 |
| Option | 126,235 | — | $4.70 |
| Option | 54,690 | — | $5.75 |
| Option | 132,500 | — | $9.83 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Y-mAbs Therapeutics, Inc.'s FY2024 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
20 Form 4 lines since the FY2024 proxy (filed May 30, 2025)current to 2026-11-07 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2025-09-16 | Disposition to the issuer derivative | — | 130,000 | — | 0 |
| 2025-09-16 | U | — | 67,681 | $8.60 | 0 |
| 2025-09-16 | Disposition to the issuer derivative | — | 16,000 | — | 0 |
| 2025-09-16 | U | — | 245,486 | $8.60 | 0 |
| 2025-09-16 | U | — | 60,000 | $8.60 | 0 |
| 2025-09-16 | Disposition to the issuer derivative | — | 143,169 | — | 0 |
| 2025-09-16 | Disposition to the issuer derivative | — | 16,000 | — | 0 |
| 2025-09-16 | Disposition to the issuer | — | 60,235 | — | 0 |
The 8 most recent of 20 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
Y-mAbs Therapeutics’s named executive officers, FY2024
as the company reported each| Named executive officer | Role | FY2024 total |
|---|---|---|
| Michael Rossi | President and Chief Executive Officer | $4,557,590 |
| Peter Pfreundschuh | Treasurer and Chief Financial Officer | $2,504,717 |
| Thomas Gad · this page | Founder, Chief Business Officer and Vice Chairman of the Board of Directors | $2,075,163 |
Board service
Y-mAbs Therapeutics board · FY2024How this board is paid
Company policy: Y-mAbs Therapeutics pays directors a $50,000 cash retainer and $127,500 in RSUs/Options. As stated in Y-mAbs Therapeutics's FY2024 proxy.
The full Y-mAbs Therapeutics compensation record
free company briefThis page is one person within Y-mAbs Therapeutics's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Y-mAbs Therapeutics proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Y-mAbs Therapeutics's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Y-mAbs Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.